Trial Profile
A retrospective study evaluating effect of baseline retinopathy status on efficacy of intravitreal ranibizumab therapy for diabetic macular oedema
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jan 2018
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 22 Jan 2018 New trial record
- 01 Sep 2017 Primary end point (Change in Central Subfield Thickness between groups) has been met as peer the results published in the Eye